Sophia Randolph Sells 3,273 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Sophia Randolph sold 3,273 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $5.82, for a total value of $19,048.86. Following the completion of the transaction, the insider now directly owns 327,076 shares in the company, valued at $1,903,582.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Sophia Randolph also recently made the following trade(s):

• On Monday, May 13th, Sophia Randolph sold 12,000 shares of ALX Oncology stock. The shares were sold at an average price of $15.94, for a total value of $191,280.00.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $5.60 on Friday. ALX Oncology Holdings Inc. has a twelve month low of $3.94 and a twelve month high of $17.83. The company has a current ratio of 5.21, a quick ratio of 5.21 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $291.76 million, a price-to-earnings ratio of -1.51 and a beta of 1.06. The business has a 50 day simple moving average of $11.22 and a 200-day simple moving average of $13.02.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.16. As a group, equities research analysts expect that ALX Oncology Holdings Inc. will post -2.89 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ALXO. Vestal Point Capital LP bought a new position in ALX Oncology during the 4th quarter worth $24,643,000. Redmile Group LLC boosted its position in ALX Oncology by 18.2% during the 1st quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock worth $48,241,000 after acquiring an additional 667,245 shares during the period. TD Asset Management Inc acquired a new position in ALX Oncology during the 4th quarter worth $1,048,000. abrdn plc acquired a new position in ALX Oncology during the 4th quarter worth $986,000. Finally, Vanguard Group Inc. boosted its position in ALX Oncology by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock worth $17,466,000 after acquiring an additional 64,055 shares during the period. 97.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ALXO shares. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research report on Monday, June 10th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $14.00 target price (up from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Wednesday, May 29th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.